Goldman Sachs doubles down on Novo stock target after key event

Novo Nordisk (NVO) has spent 2026 trying to convince investors that the worst is behind it. After a punishing year, the stock is finally clawing back from its lows. So, when Goldman Sachs sat down with management at a major healthcare conference this month, investors wondered if the bank would turn ...